

Supporting people who use substances in shelter settings during the COVID-19 pandemic

NATIONAL RAPID GUIDANCE RESOURCES

PROVIDERS MAY TAKE THESE KEY POINTS INTO CONSIDERATION; HOWEVER THIS DOCUMENT DOES NOT SUPERCEDE PROVINCIAL / TERRITORIAL REGULATION OR CLINICAL EXPERIENCE

General Resources

Questions and Answers - Provincial/Territorial Class Exemptions: For Supervised Consumption Site Operators

Health Canada: Subsection 56(1) Class Exemption for Patients, Practitioners and Pharmacists Prescribing and Providing Controlled Substances in Canada during the Coronavirus Pandemic

European Monitoring Centre for Drugs and Drug Addiction: EMCDDA Update on the Implications of COVID-19 for People who use Drugs (PWUD) and Drug Service Providers

Inter-Agency Standing Committee Secretariat: Interim Guidance: Scaling-Up COVID-19 Outbreak Readiness and Response Operations in Humanitarian Situations Including Camps and Camp-Like Settings

Harm Reduction and COVID-19

CRISM: Harm Reduction Worker Safety during the COVID-19 Global Pandemic

Alberta Health Services: Opioid Poisoning Response and COVID-19

BC Centre for Disease Control: COVID-19: Harm Reduction and Overdose Response

BC Centre for Disease Control, BC Ministry of Health: COVID-19: Responding to Opioid Overdoses in Overdose Prevention Services (OPS) and Supervised Consumption Sites (SCS)

Ontario Ministry of Health: COVID-19 Guidance: Consumption and Treatment Services (CTS) Sites

Yale Program in Addiction Medicine, Global Health Justice Partnership, & Crackdown: Guidance for People who use Substances on COVID-19 (Novel Coronavirus)

Pharmacotherapy and COVID-19

CRISM: Medications and other Clinical Approaches to Support Physical Distancing for People who use Substances during the COVID-19 Pandemic

CRISM: CRISM National Guideline for the Clinical Management of Opioid Use Disorder

CRISM: National Injectable Opioid Agonist Treatment for Opioid Use Disorder Clinical Guideline

United Nations Office on Drugs and Crime: Suggestions about Treatment, Care and Rehabilitation of People with Drug Use Disorder in the Context of the COVID-19 Pandemic

Harm Reduction Journal: Challenges in Maintaining Treatment Services for People who use Drugs during the COVID-19 Pandemic

CAMH, META:PHI, & OMA: COVID-19 Opioid Agonist Treatment Guidance

British Columbia Centre on Substance Use: COVID-19: Information for Opioid Agonist Treatment Prescribers and Pharmacists

British Columbia Centre on Substance Use: Risk Mitigation in the Context of Dual Public Health Emergencies

www.crism.ca/projects/covid

